Umang Swami, MD, MSCI, FASCO
@umangtalking
Followers
1K
Following
6K
Media
37
Statuses
2K
Oncologist with focus on GU cancers and melanoma. Views my own. Following or RT≠endorsement
Salt Lake City, UT
Joined February 2014
Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10)
13
101
281
RT @AndreaNecchi: 📫 Interim results of #Sunrise4 are released @TheLancetOncol .Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy i….
0
47
0
RT @neerajaiims: Congratulations Shilpa @shilpaonc and Ben @maughanonc for leading these efforts and congratulations to the team for this w….
0
19
0
RT @urotoday: EZH2 inhibition in #ProstateCancer: MEVPRO-1 phase III trial update. @neerajaiims @huntsmancancer joins @zklaassen_md @GACanc….
0
11
0
RT @neerajaiims: Who's the best candidate for Lutetium therapy? PSMA PET result matters, but 👉CT/DNA, NGS, and histology also do. Excellen….
0
26
0
RT @neerajaiims: Just started👉2025 United States #ProstateCancer Consensus Conference (USPCCC) 👉with @AlanBryce9 ‘s introductory remarks. @….
0
20
0
RT @neerajaiims: Just in @JAMANetworkOpen 👉 In pt level data from two ph3 trials (n=2187) 👉statin use associated with ⬆️ OS in advanced #pr….
0
40
0
RT @urotoday: Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to….
0
6
0
RT @avirupguha: Just in @JAMANetworkOpen -> excellent work by @Soum_Roy_RadOnc: statin exposure in apalutamide-era advanced prostate cancer….
0
6
0
RT @JAMANetworkOpen: In pts w advanced #ProstateCancer treated with apalutamide, statin exposure was associated with improved overall survi….
0
14
0
RT @DrChoueiri: Important @US_FDA Guidance for Clinical trials —no real surprises here. Some points to emphasize:. -Stats needs to be CLEAR….
0
44
0
RT @VincentRK: Academic medicine is bleeding talent. The best experts are counting to retire or switch careers at an alarming rate. It’s….
0
33
0
RT @tmprowell: #MedTwitter #OncTwitter #regulatory. 📢 NEW #FDA Draft Guidance on Overall Survival in #Oncology #ClinicalTrials, covering tr….
0
42
0
RT @tompowles1: In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Ins….
0
69
0
RT @tompowles1: IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks….
0
113
0
RT @Amolpatel_dr: Gallbladder cancer is the commonest cancer in the northern parts of India. In one of the hospital based cancer registry….
0
4
0
RT @JadChahoud: 🧪 SWOG S1512 (phase 2): In unresectable desmoplastic melanoma, pembrolizumab showed 89% ORR, 37% CR, 3-yr OS 96%. Supports….
nature.com
Nature Medicine - In cohort B of the phase 2 SWOG S1512 trial, pembrolizumab monotherapy in patients with unresectable desmoplastic melanoma elicited a complete response rate of 37% and an...
0
2
0
RT @mcuban: I just wanted to thank you for starting cost plus drugs. My husband was diagnosed with a rare autoimmune disease, Neuromyeltis….
0
832
0
RT @urotoday: Real-world treatment patterns in #mHSPC in the US. @umangtalking and @neerajaiims @huntsmancancer discuss encouraging finding….
0
2
0
RT @binayshah: Proud to co-author an op-ed with Dr. David Aboulafia in @seattletimes on the devastating impact of proposed federal cuts to….
0
5
0
RT @tompowles1: Biomarkers from adjuvant nivolumab(PD-1) vs placebo in UC shows ⬆️ TC PD-L1, CD4/8, IFNγ,TMB/APOBEC in responders & ⬆️TGFb….
0
32
0